Membranous nephropathy
Conditions
Interventions
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with IMN by clinical and pathological examination; 2. Aged 18-70 years; 3. After 3 months or more of treatment with sufficient doses of ACEI or ARB and immunosuppressive agents; 24-hour proteinuria (UTP) >= 3.5g; 4. Stable blood pressure, =45ml/min/1.73m^2; 6. Agree to maintain stable diet and sodium intake during the study period; 7. Agree and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Unstable urine protein quantification in the last 2 months, 24-hour urine protein quantification fluctuation >2g/d; 2. Complicated with chronic liver disease, or liver enzymes more than 3 times the upper limit of normal; 3. New-onset cardiovascular and cerebrovascular diseases (acute coronary syndrome, heart failure, cerebral infarction, stroke) within 3 months; 4. Uncontrolled severe hypertension; 5. Malignant tumor; 6. Patients with severe infection; 7. Hypersensitivity or other contraindications to Taitacept; 8. During pregnancy or breastfeeding; 9. Life expectancy is less than 6 months; 10. Currently participating in other clinical studies; 11. Other circumstances that the researcher considers unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 urine protein; | — |
Secondary
| Measure | Time frame |
|---|---|
| eGFR;plasma albumin;drug side effects; | — |
Countries
China
Contacts
Public ContactYang Xiangdong
Outcome results
None listed